Lorillard
Charles Pfizer and Company, Incorporated
Fields
- Document File
- 95309250/95309759/Research Sponsored by Lorillard Prior to 530000 (Summaries & Documents)
- Alias
- 89749542
- Type
- SCRT, SCIENTIFIC REPORT
- Area
- SPEARS,ALEXANDER/BASEMENT GMP
- Litigation
- Feda/Produced
- Site
- G65
- Master ID
- 95309251/9758
Related Documents:- 95309280-9286 Dr. Sperti, Research Conducted From 410000 to 450000 for Lorillard
- 95309387 Untitled Document 95309387
- 95309501-9513 Research at Ohio State University
- 95309514 Untitled Document 95309514
- 95309515 Untitled Document 95309515
- 95309516-9534 Investigation of Study of Cigarette Smoke Progress Summary - Including Survey of Literature Report No 7 Proj. 257
- 95309538-9553 The Composition of Cigarette Smoke the Gaseous Phase
- 95309554-9558 Investigation of Study of Cigarette Smoke Progress Report for Period 470401 to 470501. Report No. 8
- 95309579-9589 Killian Research Laboratories, Inc. 490000 - 550000
- 95309591-9595 Untitled Document 95309591/9595
- 95309596-9651 Experimental Studies of Some Physical and Chemical Characteristics of Four Brands of Regular Size and King Size Cigarettes with Particular Reference to Embassy Cigarettes
- 95309652-9658 Experimental Studies of the Relationship of Physical and Chemical Characteristics of Smoke to Varying Lengths of Smoked Segments of Cigarettes 1 - Correlations of Temperatures of Smoke with Variations in Lengths of Smoked Segments of Cigarettes
- 95309659-9661 Untitled Document 95309659/9661
- 95309663-9696 Comparative Analytical Studies of Smoke of Embassy Cigarettes and of Smoke of Samples of Regular Size Cigarettes
- 95309697-9699 Untitled Document 95309697/9699
- 95309700-9701 Untitled Document 95309700/9701
- 95309702-9703 Untitled Document 95309702/9703
- 95309704-9705 Untitled Document 95309704/9705
- 95309706 Untitled Document 95309706
- 95309707-9710 Untitled Document 95309707/9710
- 95309711 Untitled Document 95309711
- 95309712-9713 Untitled Document 95309712/9713
- 95309714-9715 Untitled Document 95309714/9715
- 95309716-9717 Untitled Document 95309716/9717
- 95309718-9720 Untitled Document 95309718/9720
- 95309726 Untitled Document 95309726
- 95309727 Untitled Document 95309727
- 95309728 Untitled Document 95309728
- 95309729 Untitled Document 95309729
- 95309730-9731 Untitled Document 95309730/9731
- 95309732 Untitled Document 95309732
- 95309745-9749 Report Number 1978
- 95309750-9751 Report Number 1986 Illustrations of the Determination of Silica and Silicanes in Old Gold and Kent Cigarette Smoke
- 95309755-9758 Report Number 2157
- Named Organization
- Charles Pfizer
- Riggio Tobacco
- Request
- R1-037
- Named Person
- Fishbein, M.
- Kent, H.A.
- Lilker, J.
- Parmele, H.B.
- Kent, H.A.
- Date Loaded
- 07 Jan 2002
- UCSF Legacy ID
- apq09c00
Document Images
95u709721
,,,.;,

ID NUMBER
*01055836 (R)
01146953 (R)
01150113 (R)
01150114-0115A (R)
04364078 (R)
* = Produced
(R) = Referenced
89749545

*potassium iodate - a compound, K14
in the treatmen
membranes.
source of iodine
e
- a compound, Ki used as
fungal agent and also
hyperthyroidism.
as a topical antiseptic
of the mucous
i feed as a
expectorant, anti-
he treatment of
89749544
-3-

~
Dr. Morris Fishbein, a medicall consultant to Lorillard.
(4315fl113-f}Il5A). A research grant was to be awarded to
explore the possible use of antibiotics to reduce the nicotine
content of tobacco. A brief letter dated March 30, 1955
from Dr. Parmele to Dr. Fishbein acknowledged this news
release. Dr. Parme3.e remarked that genetically bred tobacco
with a low nicotine content lost most of its flavor but,
since this was a new method, Lorillard would follow the
progress of this new nicotine reduction method with interest.
(01146953).
One could surmise from these documents that Lorillard
was aware that nicotine reduction would result in a milder
tobacco, and that attempts att such reduction had been explored.
I believe it reasonable to say that Lorillard appeared open-
minded and willing to investigate any propositions they came
upon, providing they were of a scientifically rational
nature. From the documents compiled by a relatively thorough
computer database search, it appears Pfizer's communications
were mostly unsolicited and that Lcsrillard never engaged in
any serious attempts at investigating sub;ect matter relative
to these documents.
89749543

CHARLES PFIZER AND COMPANY, INCORPORATED '
On February 15, 1950, Dr. H. B. Parmele of Lorillard
wrote a letter to Mr. H. A. Kent, then President of Lorillard,
regarding Charles Pfizer and Company, Incorporated. Mr. Kent
had received a recuest for information from Pfizer concerning
the substitution of potassium iodide for potassium iodate.*
It seemed ~he Riggrio Tobacco Company used potassium iodide in
their cig~rettes to "combat the harmful effects of nicotine,"
and were inquiring whether the substitution of potassium iodate
for potassium iodide would be possible. (04364078). Mr. Kent
had sent the correspondence to Dr. Parmele requesting he
address this question and also-remark upon exploring the
validity of such a treatment. Dr. Parmele assured Mr. Kent
that using these salts for therapeutic benefits (throat
irritation?) had no sound scientific basis. Although obviously
ready to comply with a request by Mr. Kent for further study,
Dr. Parmele's advice was to discourage any investigation along
these lines.
The next documents faundd are dated two years later
(March 12, 1952). Pfizer had written to Lorillard requesting
information on the use of citric acid in chewing tobacco.
(41t15583fi). Lorillard informed Pfizer that citric acid
might be employed for reasons of taste and for changing cane
sugar into invert syrup. Furthermore, Dr. Parmele explained,
in reference to smoking tobacco rather than chewing tobacco,
that when nicotine reacted with citric acid to form a salt,
it became less volatile than free nicotine and was less apt
to come over in the smoke. This resulted in a milder tobacco.
(01055836).
Dated eight months later, another document was
found regarding citric acid treatment of tobacco. Apparently
this treatment was still being explored by Pfizer. Dr. Parmele
received, seemingly unsolicited, two samples of tobacco from
Pfizer; one treated with citric acid, the other untreated.
These samples were analyzed for their nicotine content by
illard. The untreated sample was unusually high in
ine content while the citric acid treated tobacco was
r than normal. It was stated that the citric treated
sample had "other unusual properties;" this was not elaborated
upon. Although Dr. Parmele invited Mr. Jay Lilker (Pfizer)
to discuss the citric acid treatment futher, Lorillard did
not appear overly enthusiastic.
The latest documents found with reference to
Pfizer are dated approximately three years later. A news
release by the President of Pfizer regarding the application
of antibiotics to growing plants was sent to Dr. Parmele by
89749542
